Reply to letter from Alvarez et al
- PMID: 33121349
- PMCID: PMC7996077
- DOI: 10.1080/21645515.2020.1813485
Reply to letter from Alvarez et al
Keywords: Influenza; Quadrivalent influenza vaccine (QIV); Spain; burden of illness; cell-based vaccines; costeffectiveness; high-risk; vaccination.
Comment on
-
Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.Hum Vaccin Immunother. 2020 Sep 1;16(9):2238-2244. doi: 10.1080/21645515.2020.1712935. Epub 2020 Feb 10. Hum Vaccin Immunother. 2020. PMID: 32040379 Free PMC article.
-
Cost-effectiveness analysis has to consider all available evidence when informing inputs.Hum Vaccin Immunother. 2021 Mar 4;17(3):694-695. doi: 10.1080/21645515.2020.1799670. Epub 2020 Sep 22. Hum Vaccin Immunother. 2021. PMID: 32961079 Free PMC article. No abstract available.
References
-
- Ruiz-Aragón, Ruiz-Aragón J, Gani R, Márquez S, Alvarez P.. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Hum Vaccin Immunother. 2020:1–7. published online February 10th, 2020. doi:10.1080/21645515.2020.1712935. - DOI - PMC - PubMed
-
- Boikos C, Sylvester GC, Sampalis JS, Mansi JA. Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018 [published online ahead of print, 2020 Apr 7]. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa371. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical